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The N17 domain mitigates nuclear toxicity
in a novel zebrafish Huntington’s disease
model
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X. William Yang2,3,4 and Shuo Lin1,5*
Abstract
Background: Although the genetic cause for Huntington’s disease (HD) has been known for over 20 years, the
mechanisms that cause the neurotoxicity and behavioral symptoms of this disease are not well understood. One
hypothesis is that N-terminal fragments of the HTT protein are the causative agents in HD and that peptide sequences
adjacent to the poly-glutamine (Q) repeats modify its toxicity. Here we test the function of the N-terminal 17 amino
acids (N17) in the context of the exon 1 fragment of HTT in a novel, inducible zebrafish model of HD.
Results: Deletion of N17 coupled with 97Q expansion (mHTT-ΔN17-exon1) resulted in a robust, rapidly progressing
movement deficit, while fish with intact N17 and 97Q expansion (mHTT-exon1) have more delayed-onset movement
deficits with slower progression. The level of mHTT-ΔN17-exon1 protein was significantly higher than mHTT-exon1,
although the mRNA level of each transgene was marginally different, suggesting that N17 may regulate HTT protein
stability in vivo. In addition, cell lineage specific induction of the mHTT-ΔN17-exon1 transgene in neurons was sufficient
to recapitulate the consequences of ubiquitous transgene expression. Within neurons, accelerated nuclear accumulation
of the toxic HTT fragment was observed in mHTT-ΔN17-exon1 fish, demonstrating that N17 also plays an important role
in sub-cellular localization in vivo.
Conclusions: We have developed a novel, inducible zebrafish model of HD. These animals exhibit a progressive
movement deficit reminiscent of that seen in other animal models and human patients. Deletion of the N17 terminal
amino acids of the huntingtin fragment results in an accelerated HD-like phenotype that may be due to enhanced
protein stability and nuclear accumulation of HTT. These transgenic lines will provide a valuable new tool to study
mechanisms of HD at the behavioral, cellular, and molecular levels. Future experiments will be focused on identifying
genetic modifiers, mechanisms and therapeutics that alleviate polyQ aggregation in the nucleus of neurons.
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Background
Huntington’s disease (HD) is an incurable, autosomal
dominant neurodegenerative disease. Patients with HD
display progressive symptoms including psychiatric,
cognitive, and motor dysfunction, and the disease onset
is often defined by the onset of motor symptoms [1–3].
Initially, patients present with excessive movements of
the extremities and face, progressing to larger move-
ments described as chorea. Further disease progression
results in the opposite effect with patients suffering from
rigidity, akinesia, bradykinesia, and gait abnormalities.
The disease is invariably lethal 10–20 years after onset.
There is no cure for HD and treatments for the symp-
toms are of limited effectiveness.
HD is part of a broader class of neurological disorders
linked to polyglutamine (polyQ) repeat expansions
within several disease proteins [4]. All of these disorders
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are progressive, degenerative diseases with age of onset
inversely correlated with the number of polyQ repeats
within the protein. Although the genes involved in
polyQ diseases are, for the most part, broadly expressed,
each disease has a well-defined pattern of neurodegener-
ation affecting selective populations of neurons. In HD,
the medium spiny neurons (MSNs) of the striatum are
thought to be most susceptible to degeneration and
cortical pyramidal neurons are also affected [5]. The
precise mechanisms underlying such selective neuronal
vulnerability in HD remain incompletely understood.
One hypothesis is that amino acid sequences flanking
the polyQ repeat dictate the cell-type specific toxicity.
HD is caused by an expanded polyQ within the N-
terminus of the huntingtin protein (HTT) [6]. HTT is a
large, 3144 amino acids, protein that is ubiquitously
expressed, evolutionarily conserved, and has been
suggested to function as a scaffolding protein for many
cellular processes. Knockout of this gene is early embry-
onic lethal in mice suggesting an essential developmental
function [7–9], however the specific mechanisms
involved are not well understood. Histologically, a
hallmark of HD is large intracellular polyQ protein
aggregates [10]. These aggregates can be localized to
several sub-cellular regions including cytoplasmic, peri-
nuclear, and intra-nuclear [11, 12]. Although originally
thought to be disease causative, polyQ aggregates have
been suggested to be neuroprotective [13] and their role
in the disease is still unresolved. One hypothesis is that
localization of the aggregate defines its toxicity. Experi-
mental targeting of HTT-polyQ to different subcellular
compartments suggests that the nucleus is especially
sensitive to HTT-polyQ expression [14, 15]. The normal
subcellular distribution of HTT is mediated by protein-
protein interactions to regions outside the polyQ [16].
Most notably, the N-terminal 17 amino acids of HTT
(N17) have been suggested to regulate protein localization
and stability [17]. This region of the protein is evolutio-
narily conserved [18]. It functions as both a nuclear
export signal and cytoplasmic membrane association do-
main [19, 20]. Additionally, its amphipathic alpha-helical
structure [21, 22] promotes oligomer formation and accel-
erates HTT-polyQ fragment aggregation in vitro [23, 24].
Post-translational modifications of N17 are prevalent and
diverse [25]. Phosphorylation of serines 13 and 16 has
been demonstrated to reduce aggregation and toxicity
in vitro [26] and in vivo [27]. In vivo, BAC transgenic mice
expressing human mHTT-97Q lacking the N17 domain, a
deletion of 2–16 amino acid residues in otherwise full-
length mHTT context (BACHD-ΔN17), results in greatly
accelerated motor deficits including adult-onset move-
ment disorder, striatal neurodegeneration, and exclusive
nuclear mHTT aggregation formation [28]. The pheno-
types of BACHD-ΔN17 mice is dramatically accelerated
and more closely resemble clinically-manifest HD than
the BACHD mouse model expressing intact full-length
mHTT of the same polyQ length [28, 29]. Therefore N17
acts as a modulator of mHTT aggregation, subcellular
localization, and neurotoxicity.
Since the treatments available for HD are quite limited,
it is important to have preclinical models of the disease
that can be used to study mechanism and test candidate
therapeutics. Mouse models are the most popular and
have been developed over the last 18 years using conven-
tional transgenic, YAC and BAC transgenic, and gene
knock-in technologies to introduce polyQ into the
genome [30]. Some models express the entire protein
while others only use exon 1 which encodes the patho-
logical polyQ expansion. These mice develop behavioral
abnormalities and brain pathologies that recapitulate HD
to varying degrees. Recent data suggests that proteolytic
fragments containing exon 1 [31] or aberrantly spliced
transcripts of exon 1 [32] are toxic and exist in patients.
mHTT exon 1 based transgenic mice [33] have already
been demonstrated to exhibit behavioral and pathological
similarities to human disease, mHTT exon 1 based
models are likely to be relevant to aspects of the disease.
However, mammalian models are expensive to maintain
and have limited scalability. Several non-mammalian
models of polyQ toxicity have been developed in organ-
isms such as S.cerevisiae [34], c.elegans [35, 36], and
Drosophila [37]. These models are scalable for screening
compounds and genetic interactions, but lack high genetic
similarity to humans and have significantly different, or in
the case of S. cerevisiae no, nervous system. Zebrafish are
an advantageous vertebrate model organism that is genet-
ically more closely related to humans than non-vertebrate
models but is still scalable and reasonably affordable as
compared to mammalian models [38]. HTT-polyQ
toxicity has been reported in zebrafish by using mRNA or
plasmid DNA injection to acutely over-express the protein
[39, 40]. However, this model might not recapitulate
specific mechanisms of the disease due to its early
developmental effects and the extreme levels of protein
expression that are necessary to cause toxicity. A second
zebrafish model of polyQ toxicity has been reported in
which the rhodopsin promoter drives mHTT-exon1
fragment expression in photoreceptors of the retina [41].
These zebrafish exhibit specific cellular degeneration and
protein aggregation in the rod photoreceptor layer of the
retina. However, retinal degeneration is not a known path-
ology in HD. Therefore, a zebrafish model that more
closely recapitulates aspects of the human disease would
be a valuable new tool for the field.
We have generated a series of conditional transgenic
zebrafish models of HD. Using Cre-loxP technology, we
have generated inducible transgenic fish that express
HTT-exon1(25Q)-EGFP or mHTT-exon1(97Q)-EGFP
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upon Cre recombination. We have also generated comple-
mentary HTT-ΔN17-exon1(25Q)-EGFP and mHTT-
ΔN17-exon1(97Q)-EGFP lines. These latter models were
created to test if the accelerated nuclear pathogenesis and
disease-like phenotypes observed originally in BACHD-
ΔN17 mice [28] could also be seen in our zebrafish model,
and to test if N17 plays a crucial role in modifying the tox-
icities of mHTT-exon1, a disease-relevant toxic fragment
in HD [32]. Upon ubiquitous recombination, EGFP+
protein aggregates are visible within both mHTT-exon1
and mHTT-ΔN17-exon1 lines. Surprisingly, these fish
develop normally up to five weeks of age at which point
mHTT-ΔN17-exon1 lines begin to exhibit abnormal
movement and swimming behavior that progressively
worsen until the fish are unable to swim by about 12 weeks
of age. The mHTT-exon1 lines present much milder
swimming impairment that does not appear until 4 months
of age and progresses much more slowly. Additionally, we
crossed the mHTT-ΔN17-exon1 line into transgenic Cre
driver lines for neurons, glia, muscle, or vasculature. Only
fish expressing mHTT-ΔN17-exon1 specifically in neurons
developed a progressive movement disorder. Finally, we
examined the subcellular localization of mHTT-exon1
fragments in the transgenic fish and found that
mHTT-ΔN17-exon1 is enriched in the nucleus of
neurons, providing direct evidence that N17 is crucial
for cytoplasmic targeting/nuclear export of mHTT-
exon1 in vivo and further suggests the nuclear tox-
icity is key to the manifestation of disease-like pheno-
types in an HD vertebrate model. This new zebrafish
model of HD will be an invaluable tool to further
dissect the mechanisms of mutant polyQ toxicity and
to screen for potential therapeutics or genetic modi-
fiers to ameliorate disease-like phenotypes in vivo.
Results
Cre-loxP inducible expression of human HTT exon 1 in
transgenic zebrafish
Since our earlier experiments had demonstrated significant
toxicity leading to premature death of transgenic zebrafish
upon over-expression of polyQ expanded HTT, we decided
to create Cre-loxP conditionally inducible transgenic fish.
This system allows us to maintain the transgenic lines by
bypassing any toxicity by keeping the transgene switched
off until expression of Cre recombinase is introduced,
which also allows us spatial and temporal control of
expression. We chose to use the strong, ubiquitous bactin2
promoter provided with the tol2kit to drive transgene
expression [42]. Each transgene was assembled with the
bactin2 promoter, floxed mCherry, followed by one of four
HTT-exon1 cassettes (25Q, 97Q(m), ΔN17-25Q, or ΔN17-
97Q(m)) fused to GFP flanked by tol2 transposon sites
(Fig. 1a). The polyQ coding DNA sequences were mutated
at wobble sites as reported previously [29] to stabilize the
transgene and prevent the genomic instability associated
with CAG repeats. Transgenic germlines were established
for each transgene, one line was maintained for HTT-
exon1 and HTT-ΔN17-exon1 control fish while two
separate lines were maintained for mHTT-exon1 and
mHTT-ΔN17-exon1. Transgenic lines have been main-
tained to at least F6 generation with Mendelian inheritance
patterns suggesting a single insertion site is present in each
line. Additionally, the use of the Tol2 system should result
in single copy transgene insertions. To confirm that these
transgenes were inducible by Cre, we injected embryos
with Cre mRNA and observed loss of mCherry expression
and induction of GFP expression in all lines (Fig. 1b and
data not shown). HTT-exon1 L1 and HTT-ΔN17-exon1
L1 lines exhibited ubiquitous, diffuse GFP expression at all
time points examined while mHTT-exon1 and
mHTT-ΔN17-exon1 lines initially had ubiquitous ex-
pression but exhibited GFP+ protein aggregates by
5 days post fertilization (dpf), most prominently in trunk
muscles (Fig. 1c). To measure the expression level of each
transgene in the different lines, western blots and qRT-
PCR were performed. Each line was crossed to heat shock
inducible Cre (HS:cre) transgenic fish and then heat
shocked at shield stage resulting in robust, ubiquitous
recombination. To evaluate protein levels, Western blots
were performed on pools of embryos from three separate
clutches harvested at 5 dpf for the HTT-GFP fusion
protein and α-tubulin as a loading control (Fig. 1d, upper
panel). Densitometry was used to measure relative protein
abundance (Fig. 1d, lower panel). Embryos lacking HS:cre
never show GFP expression (data not shown). HTT-exon1
L1 and HTT-ΔN17-exon1 L1 both exhibit strong GFP
expression upon recombination at a size slightly larger
than the predicted ~37 kDa and ~35 kDa, suggesting
post-translational modification was present. Similarly,
both mHTT-exon1 and mHTT-ΔN17-exon1 appear at
sizes larger than their predicted ~46 kDa and ~44 kDa mo-
lecular masses, which may result from aberrant conform-
ation due to the expanded polyQ and/or post-translational
modification (Fig. 1d, upper panel). mHTT-exon1 L1 and
L2 exhibit similar levels of expression that are significantly
lower than line HTT-exon1 L1, HTT-ΔN17-exon1 L1, and
both mHTT-ΔN17-exon1 lines (p < 0.01, ANOVA, Bonfer-
roni posthoc test) (Fig. 1d). mHTT-ΔN17-exon1 L1 and
L2 also exhibit similar levels of expression that are lower
than HTT-ΔN17-exon1 L1 but with only L2 reaching stat-
istical significance (p < 0.01, ANOVA, Bonferroni posthoc
test) (Fig. 1d). We were surprised to observe the lower pro-
tein levels for the mHTT-exon1 lines as compared to the
mHTT-ΔN17-exon1 lines since the transgene design and
promoter were identical. To test whether transgene mRNA
expression was responsible for the difference, we per-
formed qRT-PCR analysis on mRNA extracted from each
line. For this analysis, pools of ten GFP+ embryos from six
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Fig. 1 (See legend on next page.)
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independent clutches were assayed for each line. mRNA
levels were less varied between lines than protein, with
mHTT-exon1 L1 the only one to reach statistical signifi-
cance in comparison to HTT-exon1 L1 (p < 0.05, ANOVA,
Bonferroni posthoc test) (Fig. 1e). It is important to note
that mRNA levels between mHTT-exon1 lines and
mHTT-ΔN17-exon1 lines are similar. This is in contrast to
the protein levels, suggesting that post-translational mech-
anisms may be affecting protein abundance. In fact, the
N17 region of HTT has been described as a modifier of
protein stability, harboring both phosphorylation [26, 27]
and ubiquitination [17] sites that regulate protein degrad-
ation. Therefore, it appears that the intact N17 domain
leads to greater protein instability in this zebrafish model
and its deletion accelerates protein accumulation.
The transgenic zebrafish expressing mHTT-exon1 lacking
the N17 domain exhibits accelerated, progressive
movement disorder
Each HTT transgenic line was crossed with HS:cre and
the embryos heat shocked at shield stage to induce re-
combination or left as non-heat shocked controls. HTT-
exon1 L1 (n = 21) and HTT-ΔN17-exon1 L1 (n = 26)
both exhibited robust GFP expression and developed
normally with no behavioral changes up to 26 weeks of
age (Fig. 2a and c and Additional file 1: Movie S1 and
Additional file 2: Movie S2). mHTT-exon1 L1 (n = 16)
and L2 (n = 16) both survived early development even
though mHTT-exon1 protein aggregates were present
by 5 dpf. These fish behaved normally until 16 weeks of
age, at which point mild behavioral abnormalities, such
as abnormal swimming and immobility alternating with
jerky movement, were noted in a small number of fish
in mHTT-exon1 L1 with more fish displaying these be-
haviors over time (Fig. 2c). mHTT L2 has not displayed
any behavioral abnormalities up to 32 weeks of age.
mHTT-ΔN17-exon1 L1 (n = 10) and L2 (n = 24), in
contrast, developed a robust, progressive movement
deficit (Fig. 2b and c, and Additional file 3: Movie S3
and Additional file 4: Movie S4). mHTT-exon1,
mHTT-ΔN17-exon1 L1, and mHTT-ΔN17-exon1 L2 all
exhibit statistically significant differences in survival curve
analysis as compared to each other as well as HTT-exon1
L1, HTT-ΔN17-exon1 L1, and mHTT-exon1 L2 (Fig. 2c,
Kaplan Meier with Log Rank, p < 0.001). We grouped the
observed behaviors into three stages according to their se-
verity (Fig. 2d): Stage 1 – abnormal swimming, immobility
alternating with jerky movement; Stage 2 – loss of lateral
stability, corkscrew swimming (see Fig. 2b); Stage 3 – loss
of vertical stability, inability to coordinate swimming,
death. mHTT-exon1 L1 fish begin exhibiting symptoms at
16 weeks and slowly progress so that by 44 weeks 50 % of
the fish have reached Stage 3 (Fig. 2e). However, 40 % of
the fish are still unaffected. mHTT-ΔN17-exon1 L1 begins
exhibiting Stage 1 symptoms by 5 weeks of age and
progresses to Stage 3 by 10–12 weeks (Fig. 2f). mHTT-
ΔN17-exon1 97Q L2 does not exhibit Stage 1 symptoms
until 8 weeks and progresses more slowly with Stage 3 not
reached for all fish until after 20 weeks (Additional file 5).
These experiments have been repeated in multiple
generations with similar results. Non-heat shocked
control transgenic fish for all lines, including both
mHTT-ΔN17-exon1 lines, develop normally and do
not show abnormal movement before 1 year of age
(the last observation made), although some leaking
recombination was noted. Overall, we have found that
mHTT-ΔN17-exon1 transgenic fish consistently ex-
hibit a progressive movement deficit, while mHTT-
exon1 fish show a later-onset and more slowly
progressing behavioral impairment. Importantly, the
control HTT-exon1 and HTT-ΔN17-exon1 fish are
indistinguishable from wild-type fish. Since the phe-
notypes of the transgenic fish were analyzed up to
11 months of age, it is possible that the mHTT-exon1
zebrafish could develop more severe disease-like phe-
notypes as they age.
(See figure on previous page.)
Fig. 1 Design and demonstration of Cre-loxP inducible HTT-exon 1-GFP expression in transgenic zebrafish. a Schematic of the transgene design
using the bactin2 promoter to drive expression of floxed mCherry followed by the HTT-exon 1 cassette being tested. Following Cre expression by
mRNA injection or HS:cre transgene induction, mCherry is recombined out and the desired HTT-exon 1 cassette fused to GFP is expressed
ubiquitously. b Photo micrographs depicting 5 day old, HTT-exon1(25Q) embryos displaying mCherry expression when Cre is absent
(upper panel) or mCherry negative, HTT-exon1-GFP positive expression following cre mRNA injection (bottom two panels). c Close-up view
of the trunk of HTT(25Q)-exon1-GFP and mHTT(97Q)-exon1-GFP embryos demonstrating ubiquitous, diffuse expression of HTT-exon1-GFP
(left panel) and ubiquitous, aggregated expression of mHTT-exon1-GFP (right panel). d A representative western blot and densitometric
measurments for each transgenic line (n = 3). Anti-GFP antibody (top panel) and anti-tubulin loading controls (bottom panel) on protein
isolated from pools of 5 day old embryos for each HTT transgenic line crossed to HS:cre. 97Q and 25Q mark the location of mHTT-GFP
and HTT-GFP protein bands respectively. Protein expression was highest in HTT-exon1 L1 and HTT-ΔN17-exon1 L1 lines. mHTT-exon1 line 1(L1) and
line 2(L2) both express at similar levels as do mHTT-ΔN17-exon1 line 1(L1) and line 2(L2). Densitometric measurements (lower bar graph) demonstrate
significantly lower levels of protein in mHTT-exon1 L1 and L2 compared to all other lines while mHTT-ΔN17-exon1 L2 is significantly lower than
HTT-exon1 L1 and HTT-ΔN17-exon1 L1. Comparisons were done by one-way ANOVA with Bonferroni posthoc test, **p < 0.01, error bars are SEM.
e Quantification of transgene expression by quantitative RT-PCR. Six pools of ten embryos from separate clutches of each HTT transgenic line crossed
to HS:cre were analyzed. Comparisons of expression level were done by one-way ANOVA with Bonferonni posthoc test, *p < 0.05, error bars are SEM
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The transgenic zebrafish expressing mHTT-ΔN17-exon1
exhibit reduced brain weight
To examine if brain atrophy, a hallmark of neuropathol-
ogy in HD, was present in the mHTT-ΔN17-exon1 fish,
brain weight from Stage 3 fish was compared to non-
heat shocked fish and control HTT-ΔN17-exon1 with
and without heat shock. Fish from each group were age
matched and raised under equal population density and
tank size. This is an important consideration for zebra-
fish since they exhibit density dependent growth [43].
The average body length and weight of each group of
fish was not significantly different from each other (n = 8
for each group) (Fig. 3, a and b). The zebrafish brains
from each line (excluding the olfactory bulbs and eyes)
were dissected and weighed. Interestingly, heat shocked,
Stage 3 mHTT-ΔN17-exon1 fish exhibited a significantly
smaller brain weight than the brains from non-heat
shocked mHTT-ΔN17-exon1 fish or HTT-ΔN17-exon1
fish with or without heat shock (Fig. 3c) (ANOVA with
Bonferroni post hoc, p < 0.05). This result suggests that
mHTT-ΔN17-exon1 fish exhibit brain atrophy similar to
that seen in HD patients.
N17 domain determines the cytoplasmic versus nuclear
accumulation of mutant HTT exon1 fragments in vivo
The 17N-terminal amino acids of HTT have been re-
ported to regulate protein stability, toxicity, and sub-
cellular localization. In a mouse BACHD model with
N17 deleted in the context of the full length HTT gene,
dramatically accelerated and exclusive nuclear accumula-
tion of mHTT fragments were demonstrated [28]. In the
context of mHTT-exon1, an HD-relevant pathogenic frag-
ment [32], N17 is necessary for nuclear export/cytoplas-
mic targeting in vitro [44, 45]: its relevance in mediating
nuclear versus cytoplasmic pathology in vivo remains
unclear. Therefore, we assessed if the localization of
aggregates was different in transgenic HD fish expressing
mHTT-exon1 with or without intact N17. First, we
immunostained brain sections of Stage 3, HS:cre/
mHTT-ΔN17-exon1 fish, HS:cre/HTT-ΔN17-exon1
fish, HS:cre/mHTT-exon1 fish, and HS:cre/HTT-exon1
fish with the anti-human HTT antibody S830 [46]
(Fig. 4a–d). HTT-ΔN17-exon1 and HTT fish exhibit
diffuse staining throughout the brain with no visible
aggregates (Fig. 4a and c). mHTT-ΔN17-exon1 and
mHTT-exon1 fish both exhibit robust aggregate staining
throughout the brain (Fig. 4b and d). The aggregates in
mHTT-exon1 appear as small puncta with occasional
larger accumulations (Fig. 4b) while the aggregates in
mHTT-ΔN17-exon1 appear mainly as large oval shaped
staining reminiscent of nuclei (Fig. 4d).
To examine the cellular and subcellular localization of
these aggregates in more detail, we combined immuno-
fluorescent staining for neurons (anti-HuC) with GFP
staining of the HTT-exon1 fusion protein and DAPI for
nuclei. We focused our examination on the ventrolateral
nucleus of torus semicircularis, a brain region with
strong HuC staining and a mixture of cell bodies and
neuropil. In HTT-exon1 and HTT-ΔN17-exon1 fish,
diffuse GFP staining was present throughout the brain
including neurons (Additional file 6). Close examination
by confocal microscopy demonstrated that HTT-exon1 is
largely excluded from the nucleus while HTT-ΔN17-
exon1 is detectible in the nucleus suggesting the nuclear
export function of N17 is intact in vivo (Additional file 6).
mHTT-exon1 fish exhibited robust aggregate formation,
with the majority localized away from HuC positive neur-
onal cell bodies (Fig. 4e–h). These aggregates are likely
present in the neuropil (e.g. axons and dendrites), but it is
also possible that a subset of them are present in non-
neuronal cells. Occasional GFP+ aggregates are present in
the peri-nuclear regions stained by HuC or weakly and
diffusely in DAPI positive nuclei (Fig. 4e–h, arrowheads
highlight GFP+ nuclei). mHTT-ΔN17-exon1 fish, on the
other hand, exhibited strong and predominant nuclear ac-
cumulation of mHTT-ΔN17-exon1 that was found almost
exclusively in the HuC positive neurons (Fig. 4i–l). Neuro-
pil aggregates similar to those seen in mHTT-exon1 fish
were also present, but were much less abundant. 3D
confocal projections clearly demonstrated the neuropil
localization of HTT aggregates in mHTT-exon1 fish
(Fig. 4m) and nuclear accumulation in the mHTT-ΔN17-
exon1 fish (Fig. 4n). Quantification of HTT-GFP location
demonstrates significant enrichment of nuclear mHTT-
ΔN17-exon1 in HuC positive neurons of mHTT-ΔN17-
exon1 fish (Fig. 4o, p < 0.05, ANOVA with Bonferonni
(See figure on previous page.)
Fig. 2 mHTT-ΔN17-exon1 transgenic fish develop a progressive motor behavior phenotype. a Panels taken from Additional file 1: Movie S1 showing
normal swimming behavior in a HTT-ΔN17-exon1 transgenic fish. b Panels taken from Additional file 3: Movie S3 showing abnormal
swimming behavior, corkscrew swimming, in a mHTT-ΔN17-exon1 transgenic fish. c Disease free survival curve for each HTT-exon1
transgenic line corresponding to disease onset. Note that mHTT-ΔN17-exon1 L1 (n = 10) and L2 (n = 24) both develop symptoms earlier
than mHTT-exon1 L1 (n = 16) and that mHTT-exon1 L2 (n = 16), HTT-exon1 (n = 21), and HTT-ΔN17-exon1 (n = 26) do not exhibit symptoms in the
observed time frame. Kaplan Meier analysis with Log Rank test, p < 0.001 for mHTT-ΔN17-exon1 L1, mHTT-ΔN17-exon1 L2, and mHTT-exon1 L1.
d Behavioral characterization within different transgenic lines. Behavior was grouped into four categories: Healthy, Stage 1, Stage 2, or Stage 3 as
described. Observations were made weekly. e Disease progression of mHTT-exon1 L1 fish. Note the discontinuous x-axis to account for the extended
time frame of behavioral changes (n = 18). f Disease progression of mHTT-ΔN17-exon1 L1. mHTT-ΔN17-exon1 L1 fish developed a robust, progressive
motor behavioral deterioration beginning at 5–8 weeks of age and progressing to immobility and death by 12 weeks (n = 10)
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post hoc). No difference was detected in cell density,
percent HuC positive cells, or aggregate density (nuclear
accumulation was scored as a single aggregate) in mHTT-
exon1 versus mHTT-ΔN17-exon1 fish (Additional file 7).
Taken together, our study is consistent with the in vitro
studies in cells and mouse study with BACHD-ΔN17 mice
that N17 is a crucial element in preventing nuclear
pathogenesis for mHTT-exon1, and our study provides the
first in vivo evidence that N17 can prevent nuclear accu-
mulation and aggregation of a known pathogenic mHTT
fragment, mHTT-exon1, in a vertebrate model of HD.
Mutant HTT exon1 lacking the N17 domain exerts toxicity
selectively in neurons to induce movement deficits in HD
transgenic zebrafish
HD is generally thought to be caused by neuron specific
dysfunction and atrophy. However, since HTT expression
is ubiquitous it is possible that disease specific pathologies
are occurring in other cell types. HTT-polyQ expression
in glia [47], immune cells [48], skeletal muscle [49] and
vasculature [50, 51] have all been suggested to contribute
to HD. A recent study using conditional BAC transgenic
mouse models of HD (BACHD) revealed distinct and syn-
ergistic roles of full-length mHTT expressed in cortical
pyramidal neurons and striatal MSNs in eliciting multiple
behavioral deficits and selective neurodegeneration [52].
However, these prior models lack the overt and progres-
sive movement disorder seen in our mHTT-ΔN17-exon1
fish model, and it is unclear if mHTT-exon1 lacking N17
is ubiquitously toxic or may retain pathogenic specificity
similar to the intact mHTT-exon1. To begin answering
such a question, we crossed mHTT-ΔN17-exon1 fish with
Cre driver lines with selective Cre expression in lineages
for neurons (elavl3-Cre) [53], glia (gfap-Cre) [54], skeletal
muscle (mylpfa-Cre) [55], and endothelial (etv2-Cre) [56]
cells. Each cross gave expected tissue and cell-type specific
mHTT-exon1 transgene expression (Fig. 5a–d). GFP+ fish
from each cross were selected and raised for behavioral
observation (n = >20 for each genotype). Only the neuron
specific, elavl3:cre/mHTT-ΔN17-exon1 fish developed
movement abnormalities reminiscent of the ubiquitously
activated mHTT-ΔN17-exon1 (Fig. 5e, p < 0.001, Kaplan
Meier analysis). Using our previously described behavioral
categories, we found that elavl3:cre/mHTT-ΔN17-exon1
fish exhibit all of the progressively deteriorating move-
ment behaviors described in the ubiquitously expressing
fish (Fig. 5f). It should be noted that the movement abnor-
malities observed in elavl3:cre/mHTT-ΔN17-exon1 fish
appeared and progressed more slowly than ubiquitously
expressing fish, suggesting the possibility that non-
neuronal cells modify the effect of mHTT on neurons in
this model.
To examine the behavior of these fish in a more quan-
titative manner, we performed field potential recordings
[57] of freely behaving elavl3:cre/mHTT-ΔN17-exon1
(n = 6) and elavl3:cre/HTTΔN17 fish (n = 6) fish
(Fig. 6). elavl3:cre/mHTT-ΔN17-exon1 fish were catego-
rized as Stage 1 at the time of this experiment while
elavl3:cre/HTT-ΔN17-exon1 fish were categorized as
healthy. Field potential recordings are performed by pla-
cing individual fish into a small chamber with recording
Fig. 3 mHTT-ΔN17-exon1 transgenic fish exhibit reduced brain weight.
a Body length is not statistically different between HTT-ΔN17-exon1 and
mHTT-ΔN17-exon1 without (−HS) or with heat shock (+HS) (n= 8 for
each condition). b Body weight is not statistically different between
HTT-ΔN17-exon1 and mHTT-ΔN17-exon1 with or without heat shock
(n= 8 for each condition). c The brain weight of mHTT-ΔN17-exon1
after heat shock induction of the HTT transgene is significantly less
than either non-heat shocked mHTT-ΔN17-exon1 fish or heat shocked
HTT-ΔN17-exon1 fish (n= 8 for each condition). (*) p< 0.05 by Student’s
t-test. Error bars are SEM
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Fig. 4 mHTT-ΔN17-exon1 accumulates mainly in the nucleus of neurons while mHTT-exon1 aggregates are mostly outside the neuronal cell
body. Brain sections from 26 week old HTT-exon1 and mHTT-exon1 fish or 12 week old HTT-ΔN17-exon1 and mHTT-ΔN17-exon1, Stage 3 fish
were immunostained to observe the transgenic HTT-exon1 localization. All images are from the hindbrain region and similar staining was present
throughout all brain regions in each fish. a–d S830 anti-human HTT Exon 1 antibody was used to detect transgene expression in each transgenic
line. HTT-exon1 (a) and HTT-ΔN17-exon1 (c) tissue exhibits uniform, ubiquitous expression. mHTT-exon1 (b) tissue displays many small but distinct
aggregates while mHTT-ΔN17-exon1 (d) tissue has many large aggregates. Scale bar equals 25 μm. e–l Immunofluorescent staining of mHTT-exon1
(e–h) and mHTT-ΔN17-exon1 (i–l) transgenic fish for neurons (HuC), transgenic HTT-exon1-GFP fusion protein, and nuclei (DAPI). mHTT-exon1 tissue
exhibits many small GFP+ aggregates that are not generally associated with HuC positive neuronal cell bodies suggesting they are either in the axons
or dendrites or are non-neuronal (e–h). Occasional, weak nuclear accumulation is present in a few neurons (white arrowheads). mHTT-ΔN17-exon1
tissue has many neuronal, HuC positive, nuclei co-localized with HTT-exon1-GFP (i–l). Scale bar equals 10 μm.m and n 3D confocal projections of
mHTT-exon1 (m) and mHTT-ΔN17-exon1 (n) tissue demonstrating weak nuclear HTT-exon1-GFP staining in mHTT-exon1 and strong nuclear staining
in mHTT-ΔN17-exon1. Scale bar equals 10 μm. o Quantification of protein accumulation location. Nuclear HTT-exon1 aggregates were rare in HuC
negative cells of both lines and mHTT-exon1 transgenic HuC positive neurons. mHTT-ΔN17-exon1 transgenic fish exhibited robust nuclear accumulation
of HTT-exon1-GFP in ~40 % of HuC positive cells. ANOVA with Bonferroni posthoc test, (**) p< 0.01
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electrodes at each end. When a fish moves the electrical
activity of the muscle creates a potential across the
electrodes that can be recorded over time. This gives an
indirect measurement of each fish’s motor activity.
elavl3:cre/HTT-ΔN17-exon1 fish exhibit short bursts of
activity corresponding to swimming and turning move-
ments within the chamber (Fig. 6a, top panel). elavl3:cre/
mHTT-ΔN17-exon1 fish exhibited bouts of prolonged
activity (Fig. 6a bottom panel and c). However, elavl3:cre/
mHTT-ΔN17-exon1 fish initiated movements less
frequently than elavl3:cre/HTT-ΔN17-exon1 fish (Fig. 6b).
Overall, elavl3:cre/HTT-ΔN17-exon1 and elavl3:cre/
mHTT-ΔN17-exon1 fish did not differ in the total
amount of time they were active during these trials
(Fig. 6d). These results support the behavioral observa-
tions that Stage 1 fish exhibit bouts of jerky movement
followed by inactivity.
In summary, our cell-type-specific expression of
mHTT-ΔN17-exon1 revealed a remarkable specificity of
toxic mHTT fragments to neurons while its toxicity to
several non-neuronal cell types including glia, muscle
and blood vessels are unremarkable. This result suggests
the neurons are particularly sensitive to the nuclear
polyQ toxicity in the context of mHTT-exon1, and the
presence of N17 domain can delay such toxicity in vivo.
Discussion
The molecular mechanisms causing HD have been diffi-
cult to identify even though the specific gene mutation
has been known for 20 years. Many research models
have been created in diverse organisms such as rats [58],
mice [29, 33, 59] zebrafish [39, 40], fly [37], worm [35,
36], and yeast [34]. Mammalian models have been
extremely valuable in validating disease mechanisms and
testing candidate therapeutics [30]; they also have limita-
tions such as lack of overt disease phenotypes and
limited scalability due to the cost and effort to maintain
a large rodent colony. Invertebrate models are highly
scalable but lack close genetic homology to humans. The
zebrafish model is an ideal compromise between the
scalability of invertebrate models and genetic homology
to vertebrates. Previously developed zebrafish models of
HD are not ideal models of the disease due to lethality
caused by high level overexpression of toxic mHTT
Fig. 5 Neuron specific activation of mHTT-ΔN17-exon1 causes motor behavioral phenotype. a elavl3:cre (n = 23), b gfap:cre (n = 24), c mylpfa:cre
(n = 34), and d etv2:cre (n = 21) transgenic lines were incrossed to mHTT-ΔN17-exon1 to activate the transgene specifically in neurons, glia,
muscle, and vascular cell lineages respectively. GFP fluorescence in living embryos demonstrates the spatially restricted expression of each line
at 5 days post fertilization. e A disease free survival curve demonstrating that only elavl3:cre/mHTT-ΔN17-exon1 fish develop a behavioral
phenotype similar to ubiquitous activation of mHTT-ΔN17-exon1, p < 0.01, Kaplan Meier survival analysis. f Disease progression of elavl3:cre/
mHTT-ΔN17-exon1 fish is similar to ubiquitious mHTT-ΔN17-exon1 fish although temporally delayed, note the discontinuous x-axis
(n = 23). Behavioral Stages are described in Fig. 2
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fragments in embryos or limited disease relevance due
to restricted tissue expression.
Here we present a novel Cre-loxP inducible zebrafish
model of HD. This model allows for precise spatial and
temporal control of expression of the disease linked pro-
tein, which was previously only available in the mouse
[52, 60]. These transgenic lines can be maintained in
non-recombined form and experimental clutches of
embryos generated as needed by Cre mRNA injection or
intercross with Cre driver transgenic lines. By incrossing
tissue specific Cre driver lines to the mHTT-ΔN17-
exon1 line we found that neurons appear to be the main
cell involved in the abnormal movement behaviors
originally observed with ubiquitous expression of this
particular toxic polyQ protein. This is in agreement with
findings in conditional mouse HD models [52, 60, 61].
Future work will be necessary to establish the specific
neuronal population responsible for the behavioral
phenotype in this zebrafish model using neuronal
sub-type-specific Cre driver lines. Additionally, careful
cell-type specific analysis for histological and molecu-
lar markers of HD-like pathologies will be necessary
to further define the similarities to human disease.
These transgenic fish are based upon expression of
mHTT-exon1. In recent years it has become apparent
that the exon 1 fragment of the much larger HTT
Fig. 6 Behavioral characterization of elavl3:cre/mHTT-ΔN17-exon1. Field potential recordings were made from freely behaving elavl3:cre/HTT-ΔN17
fish (n = 6) and elavl3:cre/mHTT-ΔN17-exon1 (n = 6) fish exhibiting Stage 1 behaviors. Field potentials represent the electrical muscle activity of a
given freely behaving animal as measured by recording electrodes placed in the chamber during movements. Each fish was allowed to acclimate
to the recording chamber for 5 min and then recorded for 5 min. a Representative field potential recordings from an elavl3:cre/HTT-ΔN17-exon1
fish (top) and an elavl3:cre/mHTT-ΔN17-exon1 fish (bottom). Brackets define of swimming activity. Note the short, distinct swimming activity of
the elavl3:cre/HTT-ΔN17-exon1 fish versus the sustained activity of the elavl3:cre/mHTT-ΔN17-exon1 fish. b Average movement frequency as calculated
by counting each distinct, non-overlapping movement waveform over time. elavl3:cre/mHTT-ΔN17-exon1 fish move significantly less often than
elavl3:cre/HTT-ΔN17-exon1 fish. c elavl3:cre/mHTT-ΔN17-exon1 fish display extended periods of activity as compared to elavl3:cre/HTT-ΔN17-exon1 fish.
d Total time moving is not significantly different between elavl3:cre/HTT-ΔN17-exon1 and elavl3:cre/mHTT-ΔN17-exon1 fish. (*) p < 0.05 by
Student’s t-test. Error bars are SEM
Veldman et al. Molecular Neurodegeneration  (2015) 10:67 Page 11 of 16
protein not only contains the expanded polyQ region
that is mutated in the disease but is also a known patho-
genic species in the diseased as a result of aberrant
mHTT splicing event [32] and proteolysis [31]. A sur-
prising finding in our study is that zebrafish is somewhat
refractory to the toxicity of ubiquitously expressed
mHTT-exon1, since only a few transgenic mHTT-exon1
fish developed abnormal movements by 6 months of
age. Histological examination of these fish demonstrated
robust mHTT-exon1-GFP positive protein aggregates
formed in the brain, and most of these aggregates are lo-
cated in the neuropil (e.g. axons, dendrites). One leading
hypothesis is that the nucleus is the site of pathological
action of expanded polyQ in all polyQ disorders [4]. It
has been reported that the N17 terminal amino acids
of HTT contains a nuclear export signal [45, 62].
Additionally, these amino acids have been reported to
function in modifying aggregate formation and protein
stability [17, 23, 24, 26, 27]. Recently, Gu et. al. [28]
showed that deletion of these 17 amino acids in the con-
text of BAC transgenic mice harboring the full length hu-
man HTT gene with 97Q causes an adult-onset
progressive movement disorder and robust striatal neuro-
degeneration. Interestingly, these BACHD-ΔN17 mice
also presents with dramatic acceleration of selective nu-
clear mHTT aggregates due to accumulation of small
mHTT polyQ fragments. We therefore, tested whether
deletion of these 17 amino acids in the context of an HTT
exon 1 based transgene would cause accelerated disease in
our zebrafish model. Mutant HTT-ΔN17-exon1 expres-
sion caused a rapidly developing progressive movement
disorder that ultimately led to early death. The develop-
ment of this behavioral phenotype was correlated with
massive accumulation of mHTT-ΔN17-exon1-GFP in the
nucleus of neurons. Interestingly, although expression was
ubiquitous, large nuclear aggregates were only observed in
neurons, suggesting mechanisms of nuclear accumulation
and aggregation of the mutant polyQ protein is neuronal
selective. We did not observe robust nuclear accumulation
of the non-toxic HTT-ΔN17-exon1 transgene suggesting
that lack of N17 function alone without polyQ expansion
is not sufficient to elicit high levels of nuclear protein
accumulation. Our study confirmed and extended the
results found in BACHD-ΔN17 mice by demonstrating
not only that N17 is crucial in preventing nuclear mHTT
toxicity and onset of disease-like phenotypes in an
vertebrate, but also provide strong evidence that N17
is crucial in mitigating the ability of mHTT-exon1
fragment, a known pathogenic species in HD, to me-
diate its nuclear toxicity and disease pathogenesis in
an intact vertebrate model.
A truly surprising finding in our study is that the
mHTT-ΔN17-exon1 fragment elicits robust and progres-
sive movement disorder through its toxicity in neurons,
but not in astrocytes, skeletal muscles, or vascular cells.
This result showed that neurons, unlike the non-neuornal
cells, may have selective impairment in managing the pro-
teostasis of the expanded polyQ proteins, especially when
such protein is translocated and accumulated in the
nucleus. Our result is consistent with the rich evidence
that expanded polyQ protein is neurotoxic in an artificial
context of an endogenous protein [63], or other polyQ
diseases (e.g. SBMA or SCA1) in which nuclear transloca-
tion is essential to disease pathogenesis [4]. Our study has
important implications in the context of understand HD
pathogenesis and therapy. First, it suggests that despite
the fact that mHTT-exon1 is naturally occurring and
is more toxic than longer mHTT-exon1 fragments or
full-legnth mHTT, the N17 domain can still provide
substantial protection against its ability to translocate
into the nucleus and elicit severe disease. Second,
since in HD patients and HD mice mHTT fragments
(including exon1 fragment) eventually accumulate in
the nucleus and cause nuclear pathoglogy [10, 31],
the mHTT-ΔN17-exon1 zebrafish represent a feasible
model of HD. Thus, better understanding how N17
function is compromised in the context of HD neu-
rons or how to improve the ability of the nucleus to
clear such aberrant polyQ proteins may be important
steps in reducing disease burden in HD.
Finally, our study may have important implications in
the use of zebrafish models to study pathogenesis or
testing candidate therapeutics for HD. An important
advance we have made, through the use of conditional
genetics in zebrafish, is the creation of a stable and
robust model of HD with progressive movement deficits
and brain pathology. The inducibility of the model
allows us to study the toxicity of mutant polyQ protein
in distinct cell populations. Since the model recapitulates
aspects of the disease related to nuclear accumulation of
mHTT-polyQ fragments, our model may be particularly
useful to study mechanism and therapeutics aiming to
improve nuclear proteostasis or reduce the consequence
of nuclear mHTT toxcitiy in vivo. Moreover, due to the
robust brain atrophy associated with the overt and
progressive movement disorder, our model could also be
used to test novel neuroprotective therapies. Given the
obvious advantage of the zebrafish system in terms of its
scalability and relative low cost in its maintenance, we
envision that the mHTT-ΔN17-exon1 fish model will
facilitate the screening of potential genetic disease modi-
fiers or candidate therapeutics at a scale that is not likely
to be achievable in the other vertebrate models of HD.
Methods
Animal husbandry
All zebrafish use was approved by the University of
California, Los Angeles Animal Care and Use Committee.
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This work was performed under IACUC protocol ARC #
2001-074-41 issued by OFFICE OF ANIMAL RESEARCH
OVERSIGHT, University of California Los Angeles.
Adults, juveniles, and zebrafish embryos were maintained
according to standard zebrafish methods [64]. Heat shock
was performed on shield stage embryos for 30 min at
38.5 °C after which embryos were transferred to a stand-
ard zebrafish incubator at 28.5 °C to be raised.
Transgene constructs and generation of transgenic zebrafish
All transgenes were generated using the Multisite Gateway
System (Life Technologies) and the Tol2kit developed for
zebrafish [42]. p3E-HTT Exon 1 25Q-EGFP, p3E-HTT
Exon 1 97Q-EGFP, p3E-ΔN17 HTT Exon 1 25Q-EGFP,
and p3E −ΔN17 HTT Exon 1 97Q-EGFP were generated
by BP reaction of each respective PCR product flanked
with B2F and B3R sequences to pDONR™ P2R-P3. Trans-
gene plasmids were created by LR multisite reaction of
pDESTTol2pA, p5E-bactin2, pME-loxPmCherryloxP, and
each respective HTT p3E vector. Resulting plasmids were
injected into single cell zebrafish embryos along with Tol2
mRNA using standard methods to efficiently generate
germline integrations. Resulting F0 fish were raised and
their offspring screened for ubiquitous mCherry expres-
sion. Positive F1 embryos were raised to establish each
line. Each line was derived from separate F0 fish to control
for integration effects.
Cre driver lines were generated by LR multisite reaction
with pDESTTol2pA, promoter specific p5E vector, pME-
Cre, and p3E-pA. p5E-elav3l was generated by cloning the
3.1 kilobase zebrafish elav3l (also known as HuC)
promoter, into pDONR™ P4R-P1R using the BP reaction.
Similarly p5E-gfap was generated by subcloning the gfap
promoter from the Tg(gfap:GFP) plasmid [54] into
pDONR™ P4R-P1R. p5E-mylpfa [65] and p5E-etv2 [56]
were previously reported. Each transgenic line was gener-
ated as described above. However since these lines do not
have a fluorescent marker gene, founders were identified
by outcross to ubi:Switch fish [66] which exhibit a GFP to
mCherry fluorescent switch in tissues expressing Cre re-
combinase. Independent lines with strong tissue specific
recombination and minimal leakiness were maintained for
each promoter.
qRT-PCR
Quantitative RT-PCR was performed on cDNA generated
using Superscript III Reverse Transcriptase (Life
Technologies, 18080044) from total RNA extracted
from 5 day post fertilization larvae using Trizol reagent
(Life Technologies, 15596026) on a Stratagene Mx3005P
qPCR system. Three pools of ten embryos from sep-
arate clutches of each transgenic line were analyzed.
Oligo(dT)12-18 (Life Technologies, 18418–012) was
used to prime the reverse transcriptase reaction.
Primers were: βactin1F, TGTTTTCCCCTCCATTGTTG;
βactin1R, ACATACATGGCAGGGGTGTT; EGFPqF, AC
GTAAACGGCCACAAGTTC; EGFPqR, AAGTCGTGCT
GCTTCATGTG.
Western blotting
Western blots were performed on protein extracted
from 5 day post fertilization embryos using standard
methods. Five embryos were pooled for each sample into
25 μl of 2X SDS Loading Buffer. Protein samples were
run on a 12 % Tris-glycine acrylamide gel (Thermo
Scientific, 25247). Protein was transferred onto a PDVF
membrane (Thermo Scientific, 88520), and then probed
with rabbit anti-GFP primary antibody 1:2000 dilution
(Life Technologies, A11122), stripped and then reprobed
with mouse anti-tubulin antibody 1:10,000 dilution
(Sigma, T5168). Secondary antibodies were anti-rabbit-
peroxidase (Sigma, A0545) and anti-mouse-peroxidase
(Sigma, A9044) both at 1:5000 dilutions. Chemilumines-
cent detection was performed using Lumi-Light western
blotting reagent (Roche, 12015200001) and HyBlot CL
autoradiography film (Denville Scientific, E3018). Film
was digitized on an HP Scanjet G3110 and the image
adjusted in Adobe Photoshop CS4. ImageJ was used to
perform densitometric measurements.
Behavioral analysis
Fish were raised at similar densities and monitored
weekly for abnormal movement. Fish were grouped into
four categories: 1) Healthy – normal swimming; 2) Stage
1 – abnormal swimming, immobility alternating with
jerky movements; 3) Stage 2 – loss of lateral stability,
corkscrew swimming; 4) Stage 3 – loss of vertical stability,
inability to coordinate movement, death. When fish were
no longer able to swim for feeding they were killed for
further analysis.
For more detailed behavioral analysis we performed
electric field potential recordings on freely behaving
adult elav3l:cre/HTT-ΔN17 or, Stage 1 categorized,
elav3l:cre/mHTT-ΔN17 fish (n = 6 each) according to
the methods of Issa et.al. [57]. Fish were placed into a
recording chamber and allowed to acclimate to the
chamber for 5 min. Then field potentials generated from
muscles during movement were recorded for 5 min for
each fish. The recording chamber was 11 cm long ×
4 cm wide × 3 cm deep containing double distilled water
with a resistance of ~ 15 MΩ. Water depth was 2.75 cm.
Room temperature was set to 25 °C. Electric field poten-
tials were recorded using one pair of electrodes (0.5 cm
exposure, 0.1 cm thick of bare copper medal) placed on
either end of each testing chamber. Electric signals were
amplified 1000-fold using an AC differential amplifier
(AM-Systems model 1700, Carlsborg, WA USA), low-
pass filtered at 300 Hz and high-pass filtered at 500 Hz.
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All signals were digitized and stored with a Digidata-
1322A and acquired using Axoscope software (Molecular
Devices, Inc., Sunnyvale, CA, USA). Data was annotated
manually and movement frequency, duration, and total
time were calculated.
Body length, weight, and brain weight measurements
Body length and weight were measured on fish deeply
anesthetized with Tricaine solution (Sigma, A5040).
Length was measured from the tip of the jaw to the base
of the tail since the HS:cre line was in a long-fin genetic
background resulting in mixed normal and long-fin
offspring. After measuring the body, fish were killed by
exsanguination, the top of the skull removed, and the
head fixed in 4 % paraformaldehyde overnight at 4 °C to
improve tissue stability for dissection. Fish heads were
washed three times in PBS and gently dried. Brains
were carefully dissected using watchmakers forceps
from the olfactory bulb-telencephalon junction to the
hindbrain-spinal cord junction. All cranial nerves
were carefully removed except for the optic nerve and
optic tract which remained attached to the brain. The
eyes were removed. Excess liquid was removed and
brain weight was measured.
Histology and immunostaining
To harvest tissue for cryo-sectioning, adult fish were
deeply anesthetized in Tricaine solution (Sigma, A5040)
and then killed by exsanguination. The head was re-
moved as was the top of the skull. Fish heads were fixed
overnight in 4 % paraformaldahyde/PBS solution at 4 °C
with constant movement on a nutator mixer. The
following day the brain was dissected out intact from the
tip of the forebrain to the hindbrain spinal cord junction.
The brain was then fixed overnight in 4 % paraformalda-
hyde/PBS solution plus 5 % sucrose at 4 °C with constant
movement on a nutator mixer. The following day fixed
tissue was put through an increasing sucrose gradient: 5,
10, 12.5, 15, and 20 % in PB buffer, 1 h each and then
placed at 4 °C with constant movement on a nutator
mixer overnight. The following day tissue was infiltrated
with a mix of 2:1 20 % sucrose solution to OCT
Compound (Tissue-Tek, 4583) for 1 h and then snap fro-
zen in 100 % OCT in aluminum foil molds placed into a
2-methylbutane (Sigma, M32631), dry ice bath. Blocks
were stored at −80 °C until they were cut at 16 μm for
immunostaining on a Leica model CM3050S cryostat.
Immunohistochemistry was performed on cryosections
using the polyclonal sheep anti-human HTT primary
antibody S830 [46] at 1:1000 dilution. Biotinylated
anti-sheep secondary (Vector Laboratories, BA-6000)
was used at 1:200 dilution and the Vectastain ABC
Elite kit (Vector Laboratories, PK-6100) plus Vector
SG substrate (Vector Laboratories, SK-4700) used to
perform the color reaction. Sections were then counter
stained with Nuclear Red (Vector Laboratories, H-3403)
and mounted with Permount (Fisher, SP15-100).
Immunofluorescence was performed on sections using
manufacturer’s recommended protocol and dilution for
each antibody. Primary antibodies were rabbit anti-GFP
(Life Technologies, A11122), 1/200 dilution, and anti-
HuC/HuD (Life Technologies, A21271), 5 μg/mL.
Secondary antibodies were goat anti-rabbit Alexa488
IgG (Life Technologies, A11008), 1/200 dilution, and don-
key anti-mouse Rhodamine (Life Technologies, A16016),
1/200 dilution. Stained sections were mounted in Prolong
Gold Antifade with DAPI (Life Technologies, P36935).
Imaging
Images were captured on an Axioskop 2 plus microscope
(Zeiss) using 5×, 10×, or 40× objectives with a Hamamatsu
ORCA-ER camera and Volocity 5 software (Improvision).
Confocal images were collected on a Zeiss LSM 510 with a
63× oil immersion objective (NA 1.4). Adobe Photoshop
CS4 was used to adjust brightness and contrast and assem-
ble composite images.
To quantify GFP+ protein aggregates in HuC stained sec-
tions, ImageJ was used to count cell number (DAPI posi-
tive nuclei), HuC+ cells, and aggregate number. Maximum
intensity projections of 133.6 μm × 133.6 μm × 4.7 μm z-
stacks were analyzed from three non-consecutive sections
of each fish. Images were acquired such that bright GFP+
aggregates did not over saturate the image. Therefore, the
background level of GFP expression appears lower than it
actually was. Three fish were examined for each genotype.
Statistical analsysis
Student’s t-test was used for single comparisons, ANOVA
with Bonferonni posthoc test was used for multiple
comparisons, and Kaplan Meier survival analysis with Log
Rank posthoc test was used for survival curve compari-
sons with p < 0.05 set as significant for each. All statistical
analysis was performed using SPSS 14.0 software.
Conclusions
We have developed a Cre-inducible HD model in zebra-
fish base upon expression of human exon 1 of HTT.
Using this model we have demonstrated that the N17
domain is protective in the context of 97Q since its
deletion results in more severe phenotypes and earlier
lethality. Deletion of N17 results in neuron-specific ac-
cumulation of 97Q in the nucleus and neuron specific
induction of the transgene is sufficient to generate
HD-like phenotypes. Together these results support a
protective role of the N17 domain in HD possibly
through nuclear export of the pathological 97Q frag-
ment. This new zebrafish model will facilitate pharmaco-
logical, genetic, and mechanistic studies of HD.
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Additional files
Additional file 1: Movie S1. HTT-ΔN17-exon1 fish exhibiting normal
swimming behavior. (MOV 19875 kb)
Additional file 2: Movie S2. A group of HTT-ΔN17-exon1 fish exhibiting
normal swimming behavior. (MOV 6872 kb)
Additional file 3: Movie S3. A mHTT-ΔN17-exon1 fish exhibiting
abnormal movements corresponding to Stage 2. (MOV 11321 kb)
Additional file 4: Movie S4. A group of mHTT-ΔN17-exon1 fish
exhibiting abnormal movements corresponding to Stage 2 and 3.
(MOV 3295 kb)
Additional file 5: mHTT-ΔN17-exon1 L2 develops progressive
motor behavioral deficits. Similar to Line 1, Line 2 exhibits
progressive movement problems corresponding to the described
three stages of behavioral abnormality, resulting in immobility and
death (n = 24). (JPEG 238 kb)
Additional file 6: Ubiquitous HTT-exon1-GFP expression in HTT-exon1
and HTT-ΔN17-exon1 lines. 3D projections of confocal images of brain
sections from HTT-exon1 L1 (A-C) and HTT-ΔN17-exon1 L1 (D-F) stained for
GFP and HuC. Note the faint nuclear GFP staining in HTT while
HTT-ΔN17-exon1 has brighter nuclear GFP. (G) Relative nuclear GFP
intensity measurements in HuC+ cells comparing HTT-exon1-GFP versus
HTT-ΔN17-exon1, n = 10 cells each, **p < 0.01, students t-test. Measurments
were made using ImageJ and normalized to average GFP intensity across
the entire area. HTT-exon1-GFP was arbitrarily set at 100 %. HTT-ΔN17-exon1
nuclei were approximately 20 % brighter. (JPEG 1556 kb)
Additional file 7: Quantification of cell and HTT aggregate density
in mHTT and mHTT-ΔN17 fish brain sections. (A) Cell density as
measured by DAPI positive nuclei per brain volume was not significantly
different between the lines. (B) Percent of HuC positive cells over total
DAPI positive nuclei is not different between the two lines. (C) GFP+
HTT-exon1 aggregate density is not different between the two lines. All
comparisons using Student’s t-test, p < 0.05, not significant (ns). Cells and
aggregates were quantified as described in Fig. 4 and Methods. (JPEG 223 kb)
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